دورية أكاديمية
How to improve prostate biopsy detection of prostate cancer.
| العنوان: | How to improve prostate biopsy detection of prostate cancer. |
|---|---|
| المؤلفون: | Ornstein DK; Department of Surgery/Division of Urology, The University of North Carolina at Chapel Hill, 427 Burnett-Womack Building CB, #7235, Chapel Hill, NC 27599-7235, USA. ornstein@med.unc.edu, Kang J |
| المصدر: | Current urology reports [Curr Urol Rep] 2001 Jun; Vol. 2 (3), pp. 218-23. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science Country of Publication: United States NLM ID: 100900943 Publication Model: Print Cited Medium: Print ISSN: 1527-2737 (Print) Linking ISSN: 15272737 NLM ISO Abbreviation: Curr Urol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : Current Science, |
| مواضيع طبية MeSH: | Biopsy, Needle* , Sensitivity and Specificity*, Diagnostic Errors/*prevention & control , Prostatic Neoplasms/*pathology, Humans ; Male |
| مستخلص: | The combination of serum prostate-specific antigen (PSA) testing and transrectal ultrasonography is a highly effective strategy to diagnose prostate cancer at an early curable stage. Even though PSA is the most useful serum biomarker to aid in prostate cancer detection, it has limited specificity: as many as 75% of men who undergo prostate biopsy because of an elevated PSA do not have prostate cancer. Additionally, sextant prostate biopsies miss prostate cancer at least 20% of the time. To reduce the number of false-negative biopsies, many have advocated obtaining 12 or more cores in a single biopsy session. Studies have shown that this practice is safe and can enhance cancer detection modestly. Although it is unlikely that prostate cancer imaging will replace prostate biopsy in the near future, many exciting new imaging technologies should eventually improve targeting of prostate needle biopsy and reduce false-negative biopsies. Some of the most exciting areas include power Doppler sonography, microbubble intravenous ultrasound contrast agents, and magnetic resonance spectroscopy. These functional imaging modalities can assess tumor blood flow and metabolic activity at a cellular level and can detect malignant changes that may not be detected by standard anatomic imaging. |
| Number of References: | 49 |
| References: | J Urol. 1990 Feb;143(2):316-9. (PMID: 1688955) J Urol. 1998 Dec;160(6 Pt 1):2111-4. (PMID: 9817334) Radiology. 1999 Dec;213(3):919-25. (PMID: 10580976) J Urol. 1999 Oct;162(4):1318-21. (PMID: 10492188) Urology. 1998 Nov;52(5):808-13. (PMID: 9801104) Radiographics. 2000 Mar-Apr;20(2):559-71. (PMID: 10715350) Scand J Urol Nephrol. 1997 Dec;31(6):541-4. (PMID: 9458512) Radiology. 1997 Jun;203(3):645-52. (PMID: 9169683) Radiology. 1996 Aug;200(2):489-96. (PMID: 8685346) Prostate. 2000 Apr 1;43(1):43-8. (PMID: 10725864) Cancer Res. 1997 Aug 15;57(16):3398-401. (PMID: 9270004) Eur J Radiol. 2000 Jun;34(3):148-55. (PMID: 10927157) BJU Int. 2000 Jul;86 Suppl 1:123-34. (PMID: 10961282) JAMA. 1994 Feb 2;271(5):368-74. (PMID: 7506797) AJR Am J Roentgenol. 1995 Sep;165(3):741. (PMID: 7645513) AJR Am J Roentgenol. 2000 Jun;174(6):1575-80. (PMID: 10845484) AJR Am J Roentgenol. 2000 Mar;174(3):623-7. (PMID: 10701599) J Urol. 2000 Jan;163(1):168-71. (PMID: 10604338) Urology. 1999 Feb;53(2):356-8. (PMID: 9933054) Stud Health Technol Inform. 2000;70:392-8. (PMID: 10977580) J Urol. 1989 Jul;142(1):71-4; discussion 74-5. (PMID: 2659827) BJU Int. 2000 Jul;86(1):58-64. (PMID: 10886084) Eur Urol. 2000 Apr;37(4):443-8. (PMID: 10765075) Can Assoc Radiol J. 1994 Oct;45(5):387-90. (PMID: 7922720) Pathol Oncol Res. 2000;6(2):111-3. (PMID: 10936785) BJU Int. 2000 Aug;86(3):229-33. (PMID: 10930921) AJR Am J Roentgenol. 2001 Jan;176(1):17-22. (PMID: 11133530) Urology. 2001 Jan;57(1):83-90. (PMID: 11164149) Eur Urol. 2000 Jan;37(1):65-71. (PMID: 10671788) Adv Clin Path. 2000 Jul;4(3):111-20. (PMID: 11080790) Urology. 1998 Mar;51(3):449-54. (PMID: 9510351) Radiology. 1999 Nov;213(2):473-80. (PMID: 10551229) BJU Int. 2000 Jun;85(9):1053-7. (PMID: 10848693) J Urol. 1999 Oct;162(4):1314-7. (PMID: 10492187) J Urol. 2000 Aug;164(2):385-7. (PMID: 10893591) J Urol. 1998 Feb;159(2):471-5; discussion 475-6. (PMID: 9649265) Expert Opin Pharmacother. 2000 Dec;1(7):1399-411. (PMID: 11249473) Radiol Clin North Am. 2000 Jan;38(1):115-38, viii-ix. (PMID: 10664669) J Urol. 2000 Jan;163(1):152-7. (PMID: 10604335) Semin Roentgenol. 1999 Oct;34(4):284-94. (PMID: 10553604) J Urol. 1997 Jan;157(1):199-202; discussion 202-3. (PMID: 8976250) BJU Int. 2000 Jul;86 Suppl 1:11-7. (PMID: 10961270) J Urol. 2000 Jan;163(1):163-6; discussion 166-7. (PMID: 10604337) J Urol. 2000 Aug;164(2):393-6. (PMID: 10893593) Phys Med Biol. 2000 Jun;45(6):1477-94. (PMID: 10870705) J Urol. 1994 Jun;151(6):1571-4. (PMID: 7514690) J Urol. 2000 Aug;164(2):388-92. (PMID: 10893592) Clin Radiol. 2000 Feb;55(2):99-109. (PMID: 10657154) |
| تواريخ الأحداث: | Date Created: 20020627 Date Completed: 20020725 Latest Revision: 20191106 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s11934-001-0082-0 |
| PMID: | 12084268 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1527-2737 |
|---|---|
| DOI: | 10.1007/s11934-001-0082-0 |